Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia

Aldo M. Roccaro, Antonio Sacco, Emanuel N. Husu, Costas Pitsillides, Steven Vesole, Abdel Kareem Azab, Feda Azab, Molly Melhem, Hai T. Ngo, Phong Quang, Patricia Maiso, Judith Runnels, Mei Chih Liang, Kwok Kin Wong, Charles Lin, Irene M. Ghobrial

Research output: Contribution to journalArticle

77 Scopus citations

Abstract

We have previously shown clinical activity of a mammalian target of rapamycin (mTOR) complex 1 inhibitor in Waldenstrom macroglobulinemia (WM). However, 50% of patients did not respond to therapy. We therefore examined mechanisms of activation of the phosphoinositide 3-kinase (PI3K)/Akt/mTOR in WM, and mechanisms of overcoming resistance to therapy. We first demonstrated that primary WM cells show constitutive activation of the PI3K/Akt pathway, supported by decreased expression of phosphate and tensin homolog tumor suppressor gene (PTEN) at the gene and protein levels, together with constitutive activation of Akt and mTOR. We illustrated that dual targeting of the PI3K/mTOR pathway by the novel inhibitor NVP-BEZ235 showed higher cytotoxicity on WM cells compared with inhibition of the PI3K or mTOR pathways alone. In addition, NVPBEZ235 inhibited both rictor and raptor, thus abrogating the rictor-induced Akt phosphorylation. NVP-BEZ235 also induced significant cytotoxicity in WM cells in a caspase-dependent and -independent manner, through targeting the Forkhead box transcription factors. In addition, NVPBEZ235 targeted WM cells in the context of bone marrow microenvironment, leading to significant inhibition of migration, adhesion in vitro, and homing in vivo. These studies therefore show that dual targeting of the PI3K/mTOR pathway is a better modality of targeted therapy for tumors that harbor activation of the PI3K/mTOR signaling cascade, such as WM.

Original languageEnglish (US)
Pages (from-to)559-569
Number of pages11
JournalBlood
Volume115
Issue number3
DOIs
StatePublished - Jan 21 2010

Fingerprint Dive into the research topics of 'Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia'. Together they form a unique fingerprint.

  • Cite this

    Roccaro, A. M., Sacco, A., Husu, E. N., Pitsillides, C., Vesole, S., Azab, A. K., Azab, F., Melhem, M., Ngo, H. T., Quang, P., Maiso, P., Runnels, J., Liang, M. C., Wong, K. K., Lin, C., & Ghobrial, I. M. (2010). Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood, 115(3), 559-569. https://doi.org/10.1182/blood-2009-07-235747